source
- Eli Lilly to acquire AtaiBeckley for $2.8 billion, signaling deeper bet on psychedelicsEli Lilly announced on Thursday that it will acquire psychedelic drug developer AtaiBeckley. The purchase price is set at $2.8 billion paid upfront. The sizable upfront payment highlights Lilly's…
- Kelun-Biotech reports first-line success of Merck-partnered ADC sacituzumab tirumotecan in ChinaKelun-Biotech announced that its antibody‑drug conjugate sacituzumab tirumotecan, developed in partnership with Merck, achieved its primary efficacy endpoints when used as a first‑line therapy in a…